-- The United Laboratories International (HKG:3933) unit Zhuhai United Laboratories obtained approval for the new drug application of its TUL321 Capsules from the US Food and Drug Administration (FDA), according to a Tuesday Hong Kong bourse filing.
The FDA also accepted an application for the clinical trial registration of the drug.
The drug is intended to be used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy, age-related macular degeneration, multiple sclerosis, and myasthenia gravis.